Scarica l'app Stockscreener
0.185
0.38%
0.0007
Dopo l'orario di chiusura:
.18
-0.005
-2.70%
Precedente Chiudi:
$0.1843
Aprire:
$0.1904
Volume 24 ore:
338.20K
Relative Volume:
0.87
Capitalizzazione di mercato:
$7.73M
Reddito:
$20.27M
Utile/perdita netta:
$-63.80M
Rapporto P/E:
-0.1217
EPS:
-1.52
Flusso di cassa netto:
$-68.35M
1 W Prestazione:
+11.18%
1M Prestazione:
-15.10%
6M Prestazione:
-77.51%
1 anno Prestazione:
-85.32%
Intervallo 1D:
$0.1803
$0.1926
Intervallo di 1 settimana:
$0.1639
$0.20
Portata 52W:
$0.1417
$1.90
Carisma Therapeutics Inc Stock (CARM) Company Profile
Nome
Carisma Therapeutics Inc
Settore
Industria
Telefono
(267) 491-6422
Indirizzo
3675 MARKET STREET, PHILADELPHIA
Confronta CARM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CARM
Carisma Therapeutics Inc
|
0.185 | 6.95M | 20.27M | -63.80M | -68.35M | -1.52 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-12 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-12-10 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-04-11 | Iniziato | BTIG Research | Buy |
| 2023-10-03 | Iniziato | CapitalOne | Overweight |
| 2023-07-06 | Iniziato | Evercore ISI | Outperform |
| 2023-05-31 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-05-24 | Iniziato | H.C. Wainwright | Buy |
| 2023-04-14 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Carisma Therapeutics Inc Borsa (CARM) Ultime notizie
Carisma Therapeutics Inc (CARM): An Important Analyst Insights - Stocksregister
Carisma Therapeutics Inc (NASDAQ: CARM) Stock Sentiment: What’s Wall Street Saying? - Stocksregister
Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace
Carisma Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Average Recommendation of “Hold” by Brokerages - Defense World
Financial Metrics Unveiled: Carisma Therapeutics Inc (CARM)’s Key Ratios in the Spotlight - DWinneX
Carisma Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Carisma Therapeutics to Present at Upcoming Conferences - Seeking Alpha
Biopharma restructurings reflect strategy of short-term pain for long-term gains - BioWorld MedTech
Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Average Rating of “Hold” by Analysts - Defense World
Sagimet Biosciences (NASDAQ:SGMT) and Carisma Therapeutics (NASDAQ:CARM) Head-To-Head Review - Defense World
Philly weekly roundup: Carisma Therapeutics layoffs; PPA's AI ticketing; HiveBio's first cohort - Technical.ly
Carisma Therapeutics Inc’s Market Journey: Closing Weak at 0.19, Down -0.26 - DWinneX
CARISMA THERAPEUTICS Earnings Preview: Recent $CARM Insider Trading, Hedge Fund Activity, and More - Nasdaq
Carisma Therapeutics Focuses on Strategic Alternatives Amid Revised Operating Plan - MSN
Philly’s Carisma Therapeutics slashed its workforce to 6 from 46 for sale or wind down - MSN
Carisma Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Carisma Therapeutics (NASDAQ:CARM) Price Target Lowered to $1.00 at D. Boral Capital - Defense World
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Carisma Therapeutics to Present at AASLD 2024 on Liver Fibrosis Treatment - MSN
Carisma winds down operations, lays off 95% of remaining staff - Fierce Biotech
Penn spinout Carisma Therapeutics lays off 84% of its staff, explores possible sale - The Business Journals
Carisma Therapeutics Provides Corporate Updates - Citizen Tribune
Carisma Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Carisma Therapeutics Board Approves Revised Operating Plan; Reduces Workforce - MarketScreener
Carisma Therapeutics Inc. SEC 10-K Report - TradingView
Carisma Therapeutics (CARM) to Release Earnings on Monday - The AM Reporter
Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Business And Shares Still Trailing The Industry - simplywall.st
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Rating of “Hold” from Analysts - Defense World
Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annua - GuruFocus.com
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Michael Klichinsky to Speak at H.C. Wainwright Cell Therapy Virtual Conference - MSN
Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 - Quantisnow
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - Quantisnow
Carisma Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Conference - MSN
Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference - Quantisnow
Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Update - Defense World
Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Carisma Therapeutics Inc Azioni (CARM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
17.27%
1.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):